Emgality FDA Approval History
FDA Approved: Yes (First approved September 27, 2018)
Brand name: Emgality
Generic name: galcanezumab-gnlm
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Migraine Prevention, Cluster Headaches
Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine, and for the treatment of episodic cluster headache.
Development Timeline for Emgality
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.